Central nervous system
Withdrawn from the UK market because of safety concerns. The CSM has stated that there is no identifiable patient group in whom the risk:benefit of co-proxamol may be positive.
This current colour classification is in line with the recommendations contained within the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria